Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug help leukemia patients stay off cancer pills?

NCT ID NCT02889003

Recruiting now Disease control Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding pioglitazone (a diabetes drug) to standard tyrosine kinase inhibitors (TKIs) can help people with chronic myeloid leukemia (CML) who lost remission after stopping TKI therapy. Participants take the combination for at least six months, then stop all treatment to see if they can maintain remission for a year. The goal is to find a way for more patients to safely discontinue long-term TKI use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pioglitazone plus a tyrosine kinase inhibitor (TKI)
What this could lead to
If successful, this combination may allow some CML patients to safely stop TKI therapy again and remain in remission without continuous medication.
What could go wrong
This is a small, early-phase study (26 participants). The combination may cause side effects or fail to prevent relapse, and results may not apply to all CML patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA (CML)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Lyon

    RECRUITING

    Lyon, France

    Contact

  • CHU de Nantes

    WITHDRAWN

    Nantes, 44093, France

  • CHU de Rennes

    WITHDRAWN

    Rennes, 35033, France

  • Centre Hospitalier de Versailles

    RECRUITING

    Le Chesnay, 78150, France

    Contact Email: •••••@•••••

  • Hôpital Bicêtre

    WITHDRAWN

    Le Kremlin-Bicêtre, 94275, France

  • IUCT

    RECRUITING

    Toulouse, France

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.